Improved long-term biocompatibility of coronary stents by plasma coating process

Information

  • Research Project
  • 9521082
  • ApplicationId
    9521082
  • Core Project Number
    R44HL097485
  • Full Project Number
    3R44HL097485-04A1S1
  • Serial Number
    097485
  • FOA Number
    PA-17-286
  • Sub Project Id
  • Project Start Date
    9/1/2017 - 7 years ago
  • Project End Date
    3/31/2018 - 6 years ago
  • Program Officer Name
    BALDWIN, TIM
  • Budget Start Date
    9/1/2017 - 7 years ago
  • Budget End Date
    3/31/2018 - 6 years ago
  • Fiscal Year
    2017
  • Support Year
    04
  • Suffix
    A1S1
  • Award Notice Date
    8/17/2017 - 7 years ago
Organizations

Improved long-term biocompatibility of coronary stents by plasma coating process

Improved long-term biocompatibility of coronary stents by plasma coating process Abstract Drug-eluting stents (DES) have been widely used to treat patients of coronary heart disease (CHD) due to their better ability to control restenosis than bare metal stents (BMS). However, there is a high risk of late in-stent thrombosis associated with DES after implantation in patients, which could lead to fatal heart attack and death even though it occurs at low rate. Thus, for safe and effective clinical use, a coronary stent needs to have better long-term biocompatibility on its surface that will provide sufficient thrombo-resistance in addition to inhibiting smooth muscle cell proliferation thereby slowing down healing of tissues around the stent. Nanova, Inc. is developing a novel coating layer of high thrombo-resistance on the surface of stents made of stainless steel or CrCo. An environmentally benign technology, low temperature plasma process is used to deposit an ultra-thin (nano-scale) but continuous layer of coating, sufficient to generate desired abrasion resistance and immobilize the bioactive functional groups created in the subsequent surface treatment to prevent blood clotting and restenosis, but thin enough to allow for stent expansion without cracking when delivered into the atherosclerotic coronary arteries of patients. The knowledge gained in this innovative research project will also benefit research and development for improved biocompatibility for other implantable medical devices such as pacemakers, pulse generators, cardiac defibrillators and bio-sensors.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R44
  • Administering IC
    HL
  • Application Type
    3
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    42000
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:42000\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
  • Study Section Name
  • Organization Name
    NANOVA, INC.
  • Organization Department
  • Organization DUNS
    800407343
  • Organization City
    COLUMBIA
  • Organization State
    MO
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    652036469
  • Organization District
    UNITED STATES